Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.

MLA

van Wilpe, S., et al. “Ipilimumab with Nivolumab in Molecularly Selected Patients with Castration-Resistant Prostate Cancer: Primary Analysis of the Phase II INSPIRE Trial.” Annals of Oncology, vol. 35, no. 12, Dec. 2024, pp. 1126–37. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.09.004.

APA

van Wilpe, S., Kloots, I. S. H., Slootbeek, P. H. J., den Brok, M., Westdorp, H., Franken, M. D., Coskunturk, M., Osinga, T., Bloemendal, H., Adema, G., Smeenk, R. J., Nagarajah, J., van Ipenburg, J., Kroeze, L. I., Ligtenberg, M. J. L., Schalken, J., Gerritsen, W. R., & Mehra, N. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology, 35(12), 1126–1137. https://doi.org/10.1016/j.annonc.2024.09.004

Chicago

van Wilpe, S., I.S.H. Kloots, P.H.J. Slootbeek, M. den Brok, H. Westdorp, M.D. Franken, M. Coskunturk, et al. 2024. “Ipilimumab with Nivolumab in Molecularly Selected Patients with Castration-Resistant Prostate Cancer: Primary Analysis of the Phase II INSPIRE Trial.” Annals of Oncology 35 (12): 1126–37. doi:10.1016/j.annonc.2024.09.004.